Compare FUNC & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FUNC | TENX |
|---|---|---|
| Founded | 1900 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.6M | 317.8M |
| IPO Year | 2012 | 2001 |
| Metric | FUNC | TENX |
|---|---|---|
| Price | $45.14 | $13.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 23.5K | ★ 1.4M |
| Earning Date | 04-20-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.80% | N/A |
| EPS Growth | ★ 19.68 | N/A |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $18,426,000.00 | N/A |
| Revenue This Year | $13.05 | N/A |
| Revenue Next Year | $6.56 | N/A |
| P/E Ratio | $43.98 | ★ N/A |
| Revenue Growth | ★ 4.01 | N/A |
| 52 Week Low | $32.51 | $5.80 |
| 52 Week High | $46.30 | $19.40 |
| Indicator | FUNC | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 58.54 | 42.05 |
| Support Level | $36.38 | $13.13 |
| Resistance Level | $46.27 | $14.15 |
| Average True Range (ATR) | 1.19 | 1.19 |
| MACD | -0.10 | -0.36 |
| Stochastic Oscillator | 81.62 | 9.63 |
First United Corp is active in the financial services domain. The scope of its offering includes checking, savings, money market deposit accounts and certificates of deposit, business loans, personal loans, mortgage loans and lines of credit extended to both individuals and businesses. The bank also provides residential real estate construction loans to builders and individuals for single-family dwellings. The company's reportable operating segments include community banking and wealth management. The company generates the majority of its revenue from the Community Banking segment, which is engaged in delivering financial products and services, including various loan and deposit products, to consumer, business, and not-for-profit customers.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.